NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

While I would also characterize the first thirty eight blended apparent efficacy as a bust regarding 36 month survival (However, removal of 100% early psPD or undiagnosed MGMT status might explain it), some characterizations you gave I'd not agree with. To me, the next 144 did quite well at thirty-six months, and the final 149 should prove to do even better, despite the fact the second half of the trial also included sicker patients on average.

I am in alignment with this statement you made -- particularly after reevaluating LP's comments back in Sept 2014.

This publication's [May 2018] statement may be a preemptive defense of the much better overall results to come and NWBO may later explain that honing and upgrading of manufacturing is not a fundamental change and had to be carried out to meet standardization and regulatory approval with improvement of results as an unforeseen [or acceptable**] consequence. If this explanation is correct (and I am of course not sure it is) it is still bizarre to think that in a clinical trial setting, the extension of lives has to be legitimized. -- meirluc

** [ ] comment added by me.